A Randomized Double Blind Study Evaluating Duloxetine in Outpatients With MDD and Pain
A Ten-Week, Randomized, Double-Blind Study Evaluating the Efficacy of Duloxetine 60mg Once Daily Versus Placebo in Outpatients With Major Depressive Disorder and Pain
Sponsor: Boehringer Ingelheim
This PHASE3 trial investigates Depressive Disorder, Major and is currently completed. Boehringer Ingelheim leads this study, which shows 6 recorded versions since 2005 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Change History
6 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE3
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE3
▶ Show 1 earlier version
-
Jan 2017 — Jun 2018 [monthly]
Completed PHASE3
First recorded
May 2005
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Boehringer Ingelheim
- Eli Lilly and Company
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Antwerpert, Belgium, Arcachon, France, Asse, Belgium, Assebroek, Belgium, Berlin, Germany, Bielefeld, Germany, Bochum, Germany, Bratislava, Slovakia, Chemnitz, Germany, Cherbourg, France and 28 more location s